Sabizabulin (VERU-111), a novel microtubule inhibitor, significantly reduced mortality in hospitalized patients with moderate to severe COVID-19 at high risk for acute respiratory distress syndrome and death according to an interim analysis from a randomized, global phase 3 clinical trial published this week in The New England Journal of Medicine Evidence.
Compared to placebo, sabizabulin resulted in a 24.9% absolute reduction in deaths beginning within the first week of treatment. Sabizabulin also resulted in a reduction of patient days in the ICU and/or on mechanical ventilation. Veru has applied to the Food and Drug Administration for an emergency authorization of use in severely ill COVID patients.
